Weembrace Karevia is the UK arm of the Weembrace Group, a healthcare company focused on improving access to high-quality, affordable oncology therapies and supportive care. Our portfolio spans small-molecule oncology medicines alongside evidence-based onco-nutrition and onco-cosmeceutical solutions, enabling comprehensive support across the cancer pathway—from treatment to recovery.

Backed by 35+ years in pharmaceutical manufacturing, supply, and hospital distribution, Weembrace operates a controlled, quality-driven network serving government and private providers. Our partners’ facilities are WHO-GMP aligned and operate under robust SOPs covering sourcing, production, packaging, and logistics. We prioritize regulatory diligence and timely product registrations, working with local experts to ensure ethical commercialization and consistent quality in each market.

In India, Weembrace maintains full regulatory compliance across states and supports large public-sector and institutional demand with dependable service levels. Internationally, we collaborate across the Middle East, Africa, Europe, and the CIS to strengthen access to essential oncology care.

At WHX Dubai, Weembrace Karevia is seeking distribution partners, hospital and pharmacy group buyers, and health-system stakeholders interested in reliable oncology supply, co-development of formulations, and market-appropriate nutrition and dermal support for oncology patients. Our goal is consistent: safer, dependable access to cancer care products at sustainable prices.